Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study

Sao Paulo Medical Journal

Joaquim De Almeida Claro¹  José Elêrton De Aboim¹  Marcelo Maríngolo¹  Enrico Andrade¹  Wilson Aguiar¹  Marcos Nogueira¹  Archimedes Nardozza Júnior¹  Miguel Srougi¹ 

[1] ,Universidade Federal de São Paulo Escola Paulista de Medicina Urology DepartmentSão Paulo,Brazil

关键词: Prostate cancer;    Erectile dysfunction;    Self-injection therapy;    Radical prostatectomy;    Câncer da próstata;    Disfunção erétil;    Auto-injeção intracavernosa;    Prostatectomia radical;   

DOI  :  10.1590/S1516-31802001000400004

来源: SciELO

【 摘 要 】

CONTEXT: Despite the recent improvements in performing radical retropubic prostatectomy that have led to a considerable decrease in the complication rate, erectile dysfunction still represents a major problem. Moreover, less invasive treatment options that are emerging for erectile dysfunction have not shown satisfactory results in managing these patients. OBJECTIVE: To study the efficacy and side effects of self-injection therapy in the treatment of men who had become impotent after undergoing radical prostatectomy due to prostate cancer, over a study period of 96 months. DESIGN: Observational study. SETTING: University Referral Center. PARTICIPANTS: 168 patients with erectile dysfunction, aged 43 to 78 years old, who underwent radical retropubic prostatectomy due to localized prostate cancer. PROCEDURES: The patients were treated with self-injection therapy using papaverine, phentolamine and prostaglandin E1, at home. RESULTS: This study showed an acceptable 94.6% success rate, with no life-threatening complications. In addition to this, our series presented a 13.1% cure rate with this therapy. CONCLUSION: Self-injection therapy with papaverine, phentolamine and prostaglandin E1 is effective and safe in the treatment of erectile dysfunction after radical prostatectomy.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License